3d Printed Drugs Market Analysis

3D-Printed Drugs Market Restraints

Any new technology adopted will inevitably have some downsides and it can sometimes be a race against time to anticipate and then mitigate them. With regards to the 3D printed drugs market, a 3D blueprint has to be made of the patient, their medical history, the dosage required etc. With many scandals surrounding hacking and phishing of data stored online & on the cloud entering the mainstream consciousness, patients might be reluctant to disclose their medical information for 3D printed drugs. Another issue could be regarding mislabelling of blueprints, filling the wrong description or even having a higher dosage strength than advertised. 3D printing becoming commonplace could also be used to print illegal drugs, which will do little to help authorities stop the thriving black market trade for them. The main challenge for the 3D printed drugs market, however, would be a lack of regulation. Most local, domestic and international regulatory bodies have no clear laws regarding 3D printing. There is a question concerning whom the liability will fall on should the drug lead to an adverse reaction – the 3D printing company, medicine Company, or the ingredients supplier. Global nature of drugs is also another problem. Drug companies involved in the 3D printed drugs market would need to ensure that the right packaging and user instructions are accessible. It can also be a major issue printing drugs in a country which has no clear laws regarding its approval.

3D-Printed Drugs Market Key Regions

The major 3D printed drugs markets are the U.S and the E.U. This is because of the dominant role played by their pharmaceutical companies worldwide along with them having a strong domestic healthcare infrastructure. The pharmaceutical sector is highly dependent on R&D spending which also explains their continued dominance. Asia Pacific countries like China and India are expected to record the highest growth in the 3D printed drugs market due to massive investments in both R&D & the pharmaceutical industry.

3D-Printed Drugs Market Key Market Players 

There is only one company involved in the 3D printed drugs market at present. Aprecia Pharmaceuticals successfully developed the world’s first 3D printed drug called Spritam. It has gained approval from the FDA and is on sale in the U.S market at present. The rapid advancement of the technology along with falling 3D printer prices will slowly but surely encourage other players to try their hand in the 3D printed drugs market.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, types and applications.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.